The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421

Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor Clinical Trial

— MoBaCo  

Official title:

Study Single-center, Uncontrolled, Retrospective, the Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02847065
• Other study ID #: RC15_0421
• Status: Completed
• Start date: November 3, 2015
• Est. completion date: April 30, 2016

Study information

• Verified date: September 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In the US and Europe, bacteremia are ranked the 7th leading cause of death from all causes. E. coli is one of the main microorganism involved, responsible for 30% to 45% of bacteremia. In Europe, bacteremia E. coli, including BLSE phenotype, have a strong impact on public health, causing increased mortality, particularly in the elderly, and an increase in the average hospital stay. However, few studies have specifically concerned with the criteria associated with mortality of elderly patients with BLSE E. coli bacteremia. Finally, improving epidemiological knowledge of the elderly patients with bacteremia due to BLSE E. coli has importance in terms of public health and is a prerequisite to the development of preventive strategies and to improve the short-term prognosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 144
• Est. completion date: April 30, 2016
• Est. primary completion date: April 30, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 105 Years

Eligibility

Inclusion Criteria:

• All patients with positive blood culture E. coli BLSE will be included in the study. Bacteremia E. coli BLSE will be defined as the identification of one or more blood cultures positive for E. coli BLSE in patients with clinical criteria of systemic inflammatory response, at least two of the following 4 criteria:

• temperature> 38 ° C or < 36 ° C;

• heart rate> 90 beat / min;

• respiratory rate > 20 c / min or PaCO2 < 32 mmHg;

• WBC > 12,000 / microL or < 4000 / microL or 10% immature forms

Exclusion Criteria:

• For each patient included, only the first episode of bacteremia will be included in the study

Related Conditions & MeSH terms

• Bacteremia
• Beta-lactamase Extended Spectrum, E. Coli, Elderly, Mortality, Risk Factor

Locations

Country	Name	City	State
France	CHU Nantes	Nantes

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Association between advancing age and mortality at 30 days in patients with bacteremia E. coli beta-lactamase phenotype extended spectrum.		30 days